PDS Biotechnology Corp (PDSB) shareholders
Close on Nov 17, 2026Market cap $50.03MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nant Capital, LLC Joint filing with Patrick Soon-Shiong (19.90%) | 20,336,335 | 19.90% | 13D (active) | Sep 14, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PDSB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,699,315 | 3.04% | $1.50M | +68,226 | 0.00% |
| Quantinno Capital Management LP | 642,177 | 1.15% | $565.82K | New | 0.00% |
| Focus Partners Wealth | 642,177 | 1.15% | $565.82K | New | 0.00% |
| BlackRock, Inc. | 607,639 | 1.09% | $535.39K | +53,591 | 0.00% |
| Geode Capital Management, LLC | 587,139 | 1.05% | $517.41K | −73,089 | 0.00% |
| Vanguard Fiduciary Trust Co | 357,144 | 0.64% | $314.64K | +49,833 | 0.00% |
| Militia Capital Management LLC | 331,800 | 0.59% | $292.35K | New | 0.01% |
| Citadel Advisors LLC | 323,801 | 0.58% | $285.30K | New | 0.00% |
| Morgan Stanley | 313,922 | 0.56% | $276.60K | +310,000 | 0.00% |
| Blair William & Co/Il | 300,000 | 0.54% | $264.33K | – | 0.00% |
| Jane Street Group, LLC | 279,664 | 0.50% | $246.41K | New | 0.00% |
| Renaissance Technologies LLC | 252,200 | 0.45% | $222.21K | +31,400 | 0.00% |
| Inspirion Wealth Advisors, LLC | 188,995 | 0.34% | $165.18K | +7,000 | 0.02% |
| Marshall Wace, Llp | 147,171 | 0.26% | $129.51K | New | 0.00% |
| State Street Corp | 133,333 | 0.24% | $117.48K | – | 0.00% |
| Northern Trust Corp | 126,502 | 0.23% | $111.46K | +17,609 | 0.00% |
| Wells Fargo & Company/Mn | 109,000 | 0.19% | $96.04K | −1,500 | 0.00% |
| Commonwealth Equity Services, LLC | 92,997 | 0.17% | $81.94K | +2,200 | 0.00% |
| Amussen Hunsaker Associates LLC | 70,406 | 0.13% | $62.04K | −4,616 | 0.01% |
| Bank of New York Mellon Corp | 68,491 | 0.12% | $60.35K | −820 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 52 | 8M | 13.7% | 15 / 13 | 7 / 4 | 3M | 0M |
| Q1 2026 | 41 | 5M | 9.0% | 7 / 11 | 9 / 9 | 2M | 3M |
| Q4 2025 | 44 | 8M | 14.1% | 10 / 11 | 13 / 11 | 3M | 1M |
| Q3 2025 | 47 | 6M | 10.0% | 8 / 10 | 14 / 15 | 1M | 3M |
| Q2 2025 | 55 | 7M | 13.3% | 13 / 12 | 13 / 6 | 2M | 2M |
| Q1 2025 | 48 | 8M | 14.7% | 9 / 11 | 12 / 12 | 5M | 1M |
| Q4 2024 | 52 | 4M | 7.6% | 8 / 17 | 15 / 12 | 1M | 1M |
| Q3 2024 | 57 | 4M | 7.8% | 7 / 8 | 21 / 24 | 1M | 2M |
| Q2 2024 | 77 | 6M | 9.8% | 25 / 15 | 26 / 20 | 1M | 4M |
| Q1 2024 | 72 | 8M | 13.9% | 10 / 24 | 23 / 15 | 1M | 1M |
| Q4 2023 | 77 | 8M | 15.1% | 14 / 26 | 17 / 15 | 1M | 1M |
| Q3 2023 | 78 | 8M | 14.0% | 10 / 24 | 26 / 12 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
12 funds held PDSB in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PDSB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,042,050 | 1.86% | $918.15K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 583,951 | 1.04% | $514.52K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 291,913 | 0.52% | $315.27K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 189,911 | 0.34% | $167.33K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 97,931 | 0.17% | $105.77K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 88,419 | 0.16% | $95.49K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 47,619 | 0.09% | $41.96K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 25,695 | 0.05% | $22.64K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 15,312 | 0.03% | $16.54K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 12,794 | 0.02% | $11.27K | 0.01% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 311 | 0.00% | $213 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -3,600 | -0.01% | -$3.17K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frank Bedu-Addo | President/CEO, Director | 866,050 | 1.55% | Nov 17, 2026 |
| Biotechnology Corp PDS | Chief Scientific Officer | – | – | Nov 17, 2026 |
| Janetta Trochimiuk | Principal Accounting Officer | 1,124 | 0.00% | Nov 17, 2026 |
| Gregory Conn | Chief Scientific Officer | 115,545 | 0.21% | Nov 17, 2026 |
| Spencer D. Brown | Senior VP, General Counsel | – | – | Nov 17, 2026 |
| Kirk V. Shepard | Chief Medical Officer | – | – | Nov 17, 2026 |
| Stephan Toutain | Chief Operating Officer | – | – | Mar 3, 2026 |
| Lars Boesgaard | Chief Financial Officer | – | – | Mar 3, 2026 |
| John Andrew Dawson | Director | – | – | Oct 21, 2026 |
| Deborah Ramsdell | Director | – | – | Oct 20, 2026 |
| Bruce Wendel | Director | – | – | Oct 20, 2026 |
| Patrick Soon-Shiong | Director, 10% owner | – | – | Sep 21, 2026 |
| Arnold James Banaag | Director | – | – | Sep 21, 2026 |
| Otis W. Brawley | Director | – | – | Mar 3, 2026 |
| Kamil Ali-Jackson | Director | 11,764 | 0.02% | Mar 3, 2026 |
| Ilian Iliev | Director | – | – | Mar 3, 2026 |
| Gregory Gene Freitag | Director | 61,213 | 0.11% | Mar 3, 2026 |
| Stephen C. Glover | Director | 78,851 | 0.14% | Mar 3, 2026 |
| Nant Capital, LLC | 10% owner | 13,005,334 | 23.24% | Sep 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gregory Gene Freitag Director | Feb 28, 2025 | Buy | +15,060 | $1.66 | $25.00K | 61,213 |
| Stephen C. Glover Director | Feb 28, 2025 | Buy | +15,061 | $1.66 | $25.00K | 78,851 |
| Frank Bedu-Addo President/CEO, Director | Dec 2, 2022 | Option exercise | +219,535 | $6.57 | $1.44M | 866,050 |
| Frank Bedu-Addo President/CEO, Director | Dec 2, 2022 | Tax withholding | −175,184 | $9.78 | $1.71M | 690,866 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +100 | $9.00 | $900 | 3,975 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +100 | $9.00 | $900 | 4,075 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +400 | $8.90 | $3.56K | 3,875 |
| Matthew C. Hill Chief Financial Officer | Dec 13, 2021 | Buy | +2,500 | $9.00 | $22.50K | 3,475 |
| DeLyle W. Bloomquist – | Jun 16, 2021 | Option exercise | +2,970 | $5.99 | $17.79K | 183,888 |
| DeLyle W. Bloomquist – | Jun 16, 2021 | Buy | +10,000 | $9.88 | $98.80K | 193,888 |
| Voorhees Seth Van Chief Financial Officer | Jun 15, 2021 | Buy | +17,647 | $8.50 | $150.00K | 17,647 |
| Kamil Ali-Jackson Director | Jun 15, 2021 | Buy | +11,764 | $8.50 | $99.99K | 11,764 |
| Gregory Gene Freitag Director | Jun 15, 2021 | Buy | +5,882 | $8.50 | $50.00K | 46,153 |
| Stephen C. Glover Director | Jun 15, 2021 | Buy | +5,882 | $8.50 | $50.00K | 63,790 |
| Frank Bedu-Addo President/CEO, Director | Jun 15, 2021 | Option exercise | +53,174 | $6.57 | $349.35K | 673,681 |
| Frank Bedu-Addo President/CEO, Director | Jun 15, 2021 | Tax withholding | −27,166 | $12.86 | $349.35K | 646,515 |
| Gregory Gene Freitag Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 40,271 |
| Stephen C. Glover Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 57,908 |
| Richard Sykes Director | Feb 14, 2020 | Award | +384,615 | $1.30 | $500.00K | 445,108 |
| Andrew Saik Chief Financial Officer, Director | Feb 14, 2020 | Award | +38,400 | $1.30 | $49.92K | 42,549 |
| W. Bradford Middlekauff Senior VP, GC and Secretary | Mar 15, 2019 | Option exercise | +49,766 | – | – | 59,766 |
| James J. Loughlin Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 26,625 |
| R. Loch Macdonald Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 580,602 |
| Sol J. Barer Director | Mar 15, 2019 | Option exercise | +20,000 | – | – | 678,075 |
| Andrew Saik Chief Financial Officer | Mar 15, 2019 | Option exercise | +82,999 | – | – | 82,999 |
| Robert J. Spiegel Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 48,661 |
| Isaac Blech Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Brian A. Leuthner President and CEO, Director | Mar 15, 2019 | Option exercise | +169,032 | – | – | 239,268 |
| Isaac Blech Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Rosemary A. Crane Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Liam Ratcliffe Director | Mar 15, 2019 | Option exercise | +10,000 | – | – | 10,000 |
| Kurt G. Conti Director | Mar 23, 2018 | Other | −58,476 | – | – | 0 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 22, 2018 | Sale(10b5-1 plan) | −2,500 | $16.41 | $41.03K | 570,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 21, 2018 | Sale(10b5-1 plan) | −2,500 | $16.52 | $41.30K | 573,102 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 20, 2018 | Sale(10b5-1 plan) | −5,000 | $16.47 | $82.35K | 575,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Mar 19, 2018 | Sale(10b5-1 plan) | −2,500 | $16.66 | $41.65K | 580,602 |
| Brian A. Leuthner President and CEO, Director | Mar 2, 2018 | Sale(10b5-1 plan) | −2,500 | $15.08 | $37.70K | 70,236 |
| Brian A. Leuthner President and CEO, Director | Mar 1, 2018 | Sale(10b5-1 plan) | −2,500 | $14.81 | $37.03K | 72,736 |
| Brian A. Leuthner President and CEO, Director | Feb 23, 2018 | Sale(10b5-1 plan) | −2,500 | $15.37 | $38.43K | 75,236 |
| Brian A. Leuthner President and CEO, Director | Feb 22, 2018 | Sale(10b5-1 plan) | −2,500 | $15.47 | $38.68K | 77,736 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 22, 2018 | Sale(10b5-1 plan) | −2,500 | $14.49 | $36.23K | 583,102 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 21, 2018 | Sale(10b5-1 plan) | −5,000 | $13.82 | $69.10K | 585,602 |
| R. Loch Macdonald Chief Scientific Officer, Director | Feb 20, 2018 | Sale(10b5-1 plan) | −5,000 | $13.75 | $68.75K | 590,602 |
| Brian A. Leuthner President and CEO, Director | Feb 2, 2018 | Sale(10b5-1 plan) | −2,500 | $12.96 | $32.40K | 80,236 |
| Brian A. Leuthner President and CEO, Director | Feb 1, 2018 | Sale(10b5-1 plan) | −2,500 | $13.14 | $32.85K | 82,736 |
| Brian A. Leuthner President and CEO, Director | Jan 3, 2018 | Sale(10b5-1 plan) | −2,500 | $10.11 | $25.28K | 85,236 |
| Brian A. Leuthner President and CEO, Director | Jan 2, 2018 | Sale(10b5-1 plan) | −2,500 | $10.11 | $25.28K | 87,736 |
| Brian A. Leuthner President and CEO, Director | Dec 5, 2017 | Sale(10b5-1 plan) | −2,500 | $9.68 | $24.20K | 90,236 |
| Brian A. Leuthner President and CEO, Director | Dec 4, 2017 | Sale(10b5-1 plan) | −2,500 | $9.97 | $24.93K | 92,736 |
| Brian A. Leuthner President and CEO, Director | Dec 1, 2017 | Sale(10b5-1 plan) | −2,500 | $9.92 | $24.80K | 95,236 |
| Albert N. Marchio Ii Chief Accounting & Adm Officer | Nov 22, 2017 | Sale | −3,361 | $10.00 | $33.61K | 0 |
| Brian A. Leuthner President and CEO, Director | Nov 3, 2017 | Sale(10b5-1 plan) | −2,500 | $10.86 | $27.15K | 97,736 |
| Brian A. Leuthner President and CEO, Director | Nov 2, 2017 | Sale(10b5-1 plan) | −2,500 | $10.94 | $27.35K | 100,236 |
| Brian A. Leuthner President and CEO, Director | Nov 1, 2017 | Sale(10b5-1 plan) | −2,500 | $10.92 | $27.30K | 102,736 |
| Brian A. Leuthner President and CEO, Director | Oct 4, 2017 | Sale(10b5-1 plan) | −2,500 | $11.14 | $27.85K | 105,236 |
| Brian A. Leuthner President and CEO, Director | Oct 3, 2017 | Sale(10b5-1 plan) | −2,500 | $10.93 | $27.33K | 107,736 |
| Brian A. Leuthner President and CEO, Director | Oct 2, 2017 | Sale(10b5-1 plan) | −2,500 | $10.81 | $27.03K | 110,236 |
| Brian A. Leuthner President and CEO, Director | Sep 6, 2017 | Sale(10b5-1 plan) | −2,500 | $10.31 | $25.78K | 112,736 |
| Brian A. Leuthner President and CEO, Director | Sep 5, 2017 | Sale(10b5-1 plan) | −2,500 | $9.94 | $24.85K | 115,236 |
| Brian A. Leuthner President and CEO, Director | Sep 1, 2017 | Sale(10b5-1 plan) | −2,500 | $10.37 | $25.92K | 117,736 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of PDS Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,847,765 shares on Sep 9, 2026 over the last 90 days.
See a number that looks wrong?